Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 pol epitopes

Journal of Immunology

Volumn 172, Issue 11, 2004, Pages 7212-7219

  Mason, Rosemarie D ^a   Bowmer, M Ian ^a,b   Howley, Constance M ^b   Gallant, Maureen ^a   Myers, Jennifer C E ^a   Grant, Michael D ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Hlth Care Corporation of St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD8 ANTIGEN; CYTOKINE; DIDANOSINE; EFAVIRENZ; EPITOPE; GAMMA INTERFERON; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; POL PROTEIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 2442701504     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.11.7212     Document Type: Article

References (25)

1. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah, et al. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59.
2. Makedonas, G., J. Bruneau, H. Lin, R. P. Sekaly, F. Lamothe, and N. F. Bernard. 2002. HIV-specific CD8 T-cell activity in uninfected injection drug users is associated with maintenance of seronegativity. AIDS 16:1595.
3. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650.
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103.
5. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201.
6. Pantaleo, G., S. Menzo, M. Vaccarezza, C. Graziosi, O. J. Cohen, J. F. Demarest, D. Montefiori, J. M. Orenstein, C. Fox, L. K. Schrager, et al. 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332:209.
7. + lymphocytes. Science 283:857.
8. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991.
9. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, et al. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212.
10. Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, et al. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335.
11. Purbhoo, M. A., A. K. Sewell, P. Klenerman, P. J. Goulder, K. L. Hilyard, J. I. Bell, B. K. Jakobsen, and R. E. Phillips. 1998. Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. Proc. Natl. Acad. Sci. USA 95:4527.
12. McMichael, A. J., and S. L. Rowland-Jones. 2001. Cellular immune responses to HIV. Nature 410:980.
13. Del Val, M., H. J. Schlicht, T. Ruppert, M. J. Reddehase, and U. H. Koszinowski, 1991. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66:1145.
14. Korber, B., C. Brander, B. F. Haynes, R. Koup, C. Kuiken, J. P. Moore, B. D. Walker, and D. I. Watkins. 2002. HIV Molecular Immunology Database. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos.
15. Terasaki, P. I., D. Bernoco, M. S. Park, G. Ozturk, and Y. Iwaki. 1978. Microdroplet testing for HLA-A, -B, -C and -D antigens. Am. J. Clin. Pathol. 69:103.
16. Lalvani, A., T. Dong, G. Ogg, A. A. Patham, H. Newell, A. V. Hill, A. J. McMichael, and S. Rowland-Jones. 1997. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. J. Immunol. Methods 210:65.
17. Flexner, C., S. S. Broyles, P. Earl, S. Chakrabarti, and B. Moss. 1988. Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses. Virology 166:339.
18. Schmitt, M., E. Harrer, A. Goldwich, M. Bauerle, I. Graedner, J. R. Kalden, and T. Harrer, 2000. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 14:653.
19. Samri, A., G. Haas, J. Duntze, J. M. Bouley, V. Calvez, C. Katlama, and B. Autran. 2000. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 74:9306.
20. Karlsson, A. C., S. G. Deeks, J. D. Barbour, B. D. Heiken, S. R. Younger, R. Hoh, M. Lane, M. Sallberg, G. M. Ortiz, J. F. Demarest, et al. 2003, Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J. Virol. 77:6743.
21. Alexander, C. S., W. Dong, M. T. Schechter, M. V. O'Shaughnessy, S. A. Strathdee, T. Mo, J. S. Montaner, and P. R. Harrigan. 1999. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. AIDS 13:981.
22. Yerly, S., L. Kaiser, E. Race, J. P. Bru, F. Clavel, and L. Perrin. 1999, Transmission of antiretroviral-drug-resistant HIV-1 variants, Lancet 354:729.
23. Lamhamedi-Cherradi, S., B. Culmann-Penciolelli, B. Guy, M. P. Kieny, F. Dreyfus, A. G. Saimot, D. Sereni, D. Sicard, J. P. Levy, and E. Gomard, 1992. Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS 11:1249.
24. Larsson, M., X. Jin, B. Ramratnam, G. S. Ogg, J. Engelmayer, M. A. Demoitie, A. J. McMichael, W. I. Cox, R. M. Steinman, D. Nixon, et al. 1999. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 13:766.
25. Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal, 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439.